Orca Bio is a developer of cell therapy products that are meticulously designed to replace diseased blood and immune systems with healthy ones in patients. The company excels in pioneering novel cell therapies through extensive research and development, aiming to revolutionize every aspect of bone marrow transplant. This enables a life-saving platform for numerous diseases, thereby assisting healthcare professionals in providing efficient treatment for their patients.

Investors Include:

DCVC Bio, StartX (US), Highbury Group, Kaiser Foundation Hospitals, Valley Capital Partners, Dream Variation Ventures, Seraph, Edgewood Ventures, 8VC, Be The Match, Richard Klausner, Industrial Investors Group, DCVC, Kaiser Permanente, ND Capital, Illinois Municipal Retirement Fund, Felicis, Ling Wong, Mubadala Capital.

Collective explained in 2 minutes

Learn how Collective's solutions enable you to manage your risk and maximize your wealth

Learn more

Our available services for this company

Lifetime IncomeCharitable Remainder Trust

Tax SavingsDonor Advised Fund